Physician profile
Aaron J Benjamin
NPI 1699954537
$105,031.12
in general payments reported to CMS, 2019-2025
9 companies · $17.09 in 2025
The $17.09 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $25K · 2021: $20K · 2022: $23K · 2023: $3,772 · 2024: $23.80 · 2025: $17.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,752 · Food and Beverage: $40.89 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,752.00 |
| Food and Beverage | $40.89 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68,195.34 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $16,588.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $14,154.38 | 2019-2021 | |
| Medtronic Minimed, INC. | $5,860.15 | 2019-2020 | |
| Abbott Laboratories | $149.97 | 2019 | |
| Ascensia Diabetes Care US INC. | $23.80 | 2024 | |
| Antares Pharma, INC. | $21.62 | 2019 | |
| Mannkind Corporation | $20.00 | 2023 | Afrezza |
| Corcept Therapeutics | $17.09 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.